Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Asthma diagnosed by a physician at least 1 year prior to study enrollment~* Poorly-controlled asthma at study enrollment~* Non smokers (stopped smoking at least 1 year ago) and limited lifetime history of smoking~* Body mass index 30-60~* Responds to methacholine challenge test with PC20 of \<16 mg/ml~* On a stable dose of inhaled corticosteroid for at least 4 weeks prior to study entry~* FEV1 \> 60% predicted~* Able to obtain weekly weights at home~Exclusion Criteria:~* Systemic steroids within the past 4 weeks~* Lung pathology other than asthma~* Other significant non-pulmonary co-morbidities such as: coronary artery disease, peripheral vascular disease, cerebrovascular disease, congestive heart failure with an ejection fraction \<50%, liver disease or elevated liver enzymes at baseline, malignancy (excluding non-melanoma skin cancers), AIDS, renal failure with serum creatinine \>3.0, or disorders requiring steroid treatment such as vasculitis, lupus, rheumatoid arthritis~* B-type natriuretic peptide (BNP) \>400pg/ml~* Pregnant or lactating~* Currently taking a beta blocker, a CYP2C8 inhibitor or inducer such as gemfibrozil or rifampin, a TZD (thiazolidinedione), or allergic to TZD~* Taking antioxidants (if taking a multivitamin must be on a stable regimen prior to enrollment)~* Illicit drug use within the past year~* Current/active upper respiratory infection (if active URI, wait until asymptomatic for 1 week to enroll)~* Asthma exacerbation within the past 4 weeks (includes ER, urgent care, or hospital visits due to asthma resulting in an increase in asthma-related medications)~* Undergoing evaluation for sleep apnea, or plans to institute treatment for sleep apnea (patients on a stable treatment regimen for sleep apnea for the last 3 months will be allowed to participate)~* Clinically significant abnormalities present on screening 12-lead electrocardiogram~* Women of childbearing potential using oral contraceptives who are not willing to use a second method of contraception during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).